^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZenFlonate (flonoltinib)

    Associations

    News

    Trials
    Company:
    Zenitar Biomedical
    Drug class:
    JAK2 inhibitor, FLT3 inhibitor, CDK6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    13d
    Material Balance Study of [14C] Flonoltinib Maleate (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P1 trial
    |
    ZenFlonate (flonoltinib)
    2ms
    A Randomized, Open-label, Positive-controlled, Parallel-grouped, Multicenter Phase III Clinical Trial on the Efficacy and Safety of Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis (ChiCTR2600118347)
    P3, N=105, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University; Chengdu
    New P3 trial
    |
    ZenFlonate (flonoltinib)
    2ms
    A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=64, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ZenFlonate (flonoltinib)
    3ms
    Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. (PubMed, Ther Adv Hematol)
    The FMF-02 trial is the first randomized phase IIb study directly comparing the novel inhibitor FM against RUX. Its findings are expected to generate pivotal evidence regarding whether FM offers superior or differentiated clinical benefits, thereby informing its potential as a frontline therapy for intermediate- to high-risk MF and guiding the design of future phase III studies.
    P2b data • Journal
    |
    JAK2 (Janus kinase 2) • CDK6 (Cyclin-dependent kinase 6)
    |
    Jakafi (ruxolitinib) • ZenFlonate (flonoltinib)
    3ms
    Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (clinicaltrials.gov)
    P2, N=60, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Active, not recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    hydroxyurea • ZenFlonate (flonoltinib)
    3ms
    A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (clinicaltrials.gov)
    P3, N=105, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • ZenFlonate (flonoltinib)
    3ms
    A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P2 trial
    |
    ZenFlonate (flonoltinib)
    4ms
    An open-label, positive drug-controlled, parallel-group, multicenter phase II clinical trial on the efficacy, safety and pharmacokinetics of flonoltinib maleate tablet in patients with intermediate and high-risk myelofibrosis (ChiCTR2500115640)
    P2, N=75, Completed, Institute of Hematology, Chinese Academy of Medical Sciences / West China Hospital of Sichuan University; Chengdu Zenitar Biomedical Technology Co., L
    New P2 trial
    |
    ZenFlonate (flonoltinib)
    4ms
    Phase IIa study on the safety and efficacy of Flonoltinib Maleate Tablets in the treatment of patients with polycythemia vera (ChiCTR2500111413)
    P2, N=60, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University;Shengjin
    New P2 trial
    |
    hydroxyurea • ZenFlonate (flonoltinib)
    4ms
    Food Effect Study in Healthy Volunteers of Phase I Flonoltinib Maleate (ChiCTR2500115039)
    P1, N=24, Completed, Chengdu Xinhua Hospital; Chengdu Zenitar Biomedical Technology Co.Ltd.
    New P1 trial
    |
    ZenFlonate (flonoltinib)
    5ms
    A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (clinicaltrials.gov)
    P3, N=105, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P3 trial
    |
    Jakafi (ruxolitinib) • ZenFlonate (flonoltinib)
    7ms
    Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P2 trial • Tumor mutational burden
    |
    hydroxyurea • ZenFlonate (flonoltinib)